REGN — Regeneron Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Regeneron Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8,497	16,072	12,173	13,117	14,202
Cost of Revenue
Gross Profit	7,377	13,866	10,871	11,404	12,358
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	4,921	7,125	7,434	9,070	10,211
Operating Profit	3,577	8,947	4,739	4,047	3,991
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,810	9,326	4,859	4,199	4,780
Provision for Income Taxes
Net Income After Taxes	3,513	8,075	4,338	3,954	4,413
Net Income Before Extraordinary Items
Net Income	3,513	8,075	4,338	3,954	4,413
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,513	8,075	4,338	3,954	4,413
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	30.4	74.1	42.5	37.3	40.2